214 related articles for article (PubMed ID: 34011212)
41. Switching patterns of biological drugs in patients with psoriasis and psoriatic arthritis: insight from the VALORE database network.
Spini A; Pellegrini G; Ingrasciotta Y; L'Abbate L; Bellitto C; Carollo M; Leoni O; Zanforlini M; Ancona D; Stella P; Cavazzana A; Scapin A; Lopes S; Belleudi V; Ledda S; Carta P; Rossi P; Ejlli L; Sapigni E; Puccini A; Spila Alegiani S; Massari M; Guarneri C; Gisondi P; Trifirò G
Expert Opin Biol Ther; 2024 May; 24(5):399-409. PubMed ID: 38767132
[TBL] [Abstract][Full Text] [Related]
42. Efficacy, tolerability, and safety of infliximab biosimilar in comparison to originator biologic and adalimumab in patients with Crohn disease.
Kaniewska M; Rosołowski M; Rydzewska G
Pol Arch Intern Med; 2019 Aug; 129(7-8):484-489. PubMed ID: 31316042
[TBL] [Abstract][Full Text] [Related]
43. Effectiveness and safety of switching to adalimumab biosimilar ABP 501 in Crohn's disease.
Viscido A; Latella G
Rev Esp Enferm Dig; 2021 Feb; 113(2):154-155. PubMed ID: 33207902
[TBL] [Abstract][Full Text] [Related]
44. Efficacy and safety of subcutaneous anti-tumor necrosis factor-alpha agents, etanercept and adalimumab, in elderly patients affected by psoriasis and psoriatic arthritis: an observational long-term study.
Esposito M; Giunta A; Mazzotta A; Zangrilli A; Babino G; Bavetta M; Perricone R; Chimenti S; Chimenti MS
Dermatology; 2012; 225(4):312-9. PubMed ID: 23295383
[TBL] [Abstract][Full Text] [Related]
45. A randomized, double-blind phase III study to demonstrate the clinical similarity of biosimilar SCT630 to reference adalimumab in Chinese patients with moderate to severe plaque psoriasis.
Yu C; Zhang F; Ding Y; Li Y; Zhao Y; Gu J; Guo S; Pan W; Jin H; Sun Q; Kang X; Yang Q; Jiang X; Song Z; Lu Q; Pang X; Kuang Y; Deng D; Li Y; Zhang C; Tao J; Xie L; Wang Y; Wang J; Wang G
Int Immunopharmacol; 2022 Nov; 112():109248. PubMed ID: 36126411
[TBL] [Abstract][Full Text] [Related]
46. The nocebo effect challenges the non-medical infliximab switch in practice.
Boone NW; Liu L; Romberg-Camps MJ; Duijsens L; Houwen C; van der Kuy PHM; Janknegt R; Peeters R; Landewé RBM; Winkens B; van Bodegraven AA
Eur J Clin Pharmacol; 2018 May; 74(5):655-661. PubMed ID: 29368188
[TBL] [Abstract][Full Text] [Related]
47. OBSIDIAN - real-world evidence of originator to biosimilar drug switch in juvenile idiopathic arthritis.
Maccora I; Lombardi N; Crescioli G; Bettiol A; Bonaiuti R; Pagnini I; Maniscalco V; Marrani E; Mastrolia MV; Ravaldi C; Consolini R; Cattalini M; Vannacci A; Simonini G
Rheumatology (Oxford); 2022 Apr; 61(4):1518-1528. PubMed ID: 34273158
[TBL] [Abstract][Full Text] [Related]
48. Comparative efficacy and safety of biosimilar adalimumab and originator adalimumab in combination with methotrexate in patients with active rheumatoid arthritis: a Bayesian network meta-analysis of randomized controlled trials.
Bae SC; Lee YH
Clin Rheumatol; 2018 May; 37(5):1199-1205. PubMed ID: 29392511
[TBL] [Abstract][Full Text] [Related]
49. Similar efficacy, safety, and immunogenicity of the biosimilar BI 695501 and adalimumab reference product in patients with moderate-to-severe chronic plaque psoriasis: results from the randomized Phase III VOLTAIRE-PSO study.
Menter A; Arenberger P; Balser S; Beissert S; Cauthen A; Czeloth N; Soung J; Jazayeri S; Weisenseel P; Jayadeva G
Expert Opin Biol Ther; 2021 Jan; 21(1):87-96. PubMed ID: 33317345
[No Abstract] [Full Text] [Related]
50. Real-World Postmarketing Study of the Impact of Adalimumab Treatment on Work Productivity and Activity Impairment in Patients with Psoriatic Arthritis.
Nakagawa H; Tanaka Y; Sano S; Kameda H; Taniguchi A; Kashiwagi T; Kawaberi T; Kimura J; Morita A
Adv Ther; 2019 Mar; 36(3):691-707. PubMed ID: 30661197
[TBL] [Abstract][Full Text] [Related]
51. GP2017: An Adalimumab Biosimilar.
Heo YA
BioDrugs; 2018 Dec; 32(6):635-638. PubMed ID: 30460599
[TBL] [Abstract][Full Text] [Related]
52. Evaluation of the safety and effectiveness after switch from adalimumab originator to biosimilar SB5 in patients with inflammatory bowel disease in a real-life setting.
Deprez N; De Somer T; Baert D; Deceuninck M; Huys I; Mattens V; Sterckx A; Vanderstraeten E; Vandervoort J; Van Heddegem N; Dewint P
Acta Gastroenterol Belg; 2022; 85(4):557-564. PubMed ID: 36566364
[TBL] [Abstract][Full Text] [Related]
53. Predictive factors of lack of response to adalimumab among bio-naive patients suffering from moderate-to severe psoriasis: analysis of a multicenter data collection in Italy.
Zangrilli A; Caldarola G; Bernardini N; Bavetta M; Graceffa D; Bonifati C; Cantoresi F; Faleri S; Giordano D; Mariani M; Micheli A; Moretta G; Pirro F; Pagnanelli G; Panasiti V; Provini A; Richetta A; Sacchelli L; Bianchi L; Peris K
Expert Opin Biol Ther; 2021 Sep; 21(9):1291-1298. PubMed ID: 34278889
[TBL] [Abstract][Full Text] [Related]
54. Long-term data on the proposed adalimumab biosimilar BCD-057 in patients with moderate to severe psoriasis: A randomized controlled trial.
Samtsov AV; Bakulev AL; Khairutdinov VR; Kokhan MM; Korotaeva TV; Minullin IK; Vylegzhanina OA; Dubenskiy VV; Khalilov BV; Khotko AA; Zykova OS; Chumachenko IV; Lukyanov AM; Artemeva AV; Pukhtinskaia PP
PLoS One; 2022; 17(2):e0263214. PubMed ID: 35130291
[TBL] [Abstract][Full Text] [Related]
55. Review of Biosimilar Trials and Data on Adalimumab in Rheumatoid Arthritis.
Zhao S; Chadwick L; Mysler E; Moots RJ
Curr Rheumatol Rep; 2018 Aug; 20(10):57. PubMed ID: 30094742
[TBL] [Abstract][Full Text] [Related]
56. Cost Effectiveness of Secukinumab Versus Other Biologics and Apremilast in the Treatment of Active Psoriatic Arthritis in Germany.
Gandjour A; Ostwald DA
Appl Health Econ Health Policy; 2020 Feb; 18(1):109-125. PubMed ID: 31701482
[TBL] [Abstract][Full Text] [Related]
57. Adalimumab for long-term treatment of psoriatic arthritis: forty-eight week data from the adalimumab effectiveness in psoriatic arthritis trial.
Gladman DD; Mease PJ; Ritchlin CT; Choy EH; Sharp JT; Ory PA; Perdok RJ; Sasso EH
Arthritis Rheum; 2007 Feb; 56(2):476-88. PubMed ID: 17265483
[TBL] [Abstract][Full Text] [Related]
58. Real-world use of biological drugs in patients with psoriasis/psoriatic arthritis: a retrospective, population-based study of years 2010-2014 from Southern Italy.
Marcianò I; Randazzo MP; Panagia P; Intelisano R; Sgroi C; Ientile V; Cannavò S; Guarneri C; Reitano P; Spina E; Trifirò G
G Ital Dermatol Venereol; 2020 Aug; 155(4):441-451. PubMed ID: 29582617
[TBL] [Abstract][Full Text] [Related]
59. Treatment Persistence and Switching Patterns of Adalimumab Biosimilar ABP 501 in European Patients with Rheumatologic Diseases.
Jin R; Kruppert S; Scholz F; Bardoulat I; Karzazi K; Morand F; Kricorian G; Collier D; Kay J
Rheumatol Ther; 2024 Jun; 11(3):523-537. PubMed ID: 38436916
[TBL] [Abstract][Full Text] [Related]
60. Efficacy and safety evaluations of adalimumab biosimilars in the treatment of psoriasis.
Li C; Sunhe Y; Zhou H; Dong W
J Dermatolog Treat; 2023 Dec; 34(1):2249145. PubMed ID: 37608703
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
